Study | Dasatinib | Nilotinib 600 mg | Nilotinib 800 mg | Imatinib 400 mg | Imatinib 800 mg |
---|---|---|---|---|---|
Complete cytogenic response | |||||
6 months | |||||
DASISION | 73.0% | 59.2% | |||
ENESTed | 67.0% | 63.0% | 44.9% | ||
Baccarani et al. | 50.0% | 51.9% | |||
German CML Study IV | 21.5% | 33.5% | |||
Cortes et al. 2010 | 44.6% | 56.7% | |||
ISTAHIT | 19.8% | 43.8% | |||
SPIRIT | 50.0% | 69.0% | |||
12 months | |||||
DASISION study group | 83.4% | 71.5% | |||
ENESTed study group | 80.1% | 77.9% | 65.0% | ||
Baccarani et al. (2009) | 58.3% | 63.9% | |||
German CML Study IV | 49.8% | 63.2% | |||
Cortes et al. 2010 | 65.6% | 69.9% | |||
S0325 Intergroup Trial | 82.0% | 69.0% | |||
SPIRIT | 58.0% | 65.0% | |||
18 months | |||||
Dasatinib Study Group | 88.6% | ||||
DASISION study group | 78.0% | 70.0% | |||
ENESTed study group | 85.0% | 82.0% | 74.0% | ||
German CML Study IV | 66.6% | 73.8% | |||
Major Molecular response | |||||
12 months | |||||
Bacarrani et al. (2009) | 33.3% | 39.8% | |||
DASISION study group | 45.9% | 28.1% | |||
ENESTed Study group | 44.0% | 43.1% | 21.9% | ||
German CML Study IV | 30.8% | 54.8% | |||
Cortes et al. 2010 | 40.1% | 46.4% | |||
SPIRIT | 38.0% | 49.0% | |||
S0325 Intergroup Trial | 59.0% | 43.0% |